VPT:CC - Ventripoint Successfully Showcases A.I.-Powered Heart-Scanning Technology at Prestigious International Cardiology Conferences
(TheNewswire)
Hamburg, Germany — TheNewswire --- February 20, 2024 — VentripointDiagnostics Ltd. ("Ventripoint" or the "Company"),(TSXV:VPT ) ; ( OTC:VPTDF) isdelighted to report its participation at the 53rd annual meeting ofthe German Society for Thoracic, Heart and Vascular Surgery. Theevent, held Feb. 19, was held in conjunction with the annual meetingof the German Society for Paediatric Cardiology and Congenital HeartDefects in Hamburg, Germany.
Ventripoint's transformative technology, which uses a patented A.I. toconvert inferior ultrasound images into MRI-grade analysis of theheart, was demonstrated by PD Dr Med. K.T. Laser, who actively usesVentripoint in his clinical practice. You can see him in action
As a thought leader in paediatric cardiology, Dr. Laser is using theVentripoint VMS+ to image patients at the HDZ NRW Heart and DiabetesCenter in Germany. Dr. Laser's has reported that Ventripoint is aneffective diagnostic tool that allows enhanced echocardiograms ofinfants and adults to be available faster and at less cost than acardiac MRI with equivalent volumetric results.
"This was an important forum for Ventripoint to showcase ourinnovative A.I. technology to the German cardiology community,"said Bart Hendriks, Ventripoint’s Strategic Partnerships Executive."Our presence here allowed some of Europe’s top cardiologistsand health institutions to learn about and work with our technologyfirsthand."
Ventripoint’s technology is now being used in leading hospitals inEurope, the UK, Canada, and the United States. The Company is nowfocused on expanding the user base of VMS+ in hospitals and clinicsworldwide.
"I want to thank both Dr. Laser and Bart for their efforts atthis important joint conference,” said Ventripoint’s Interim CEOHugh MacNaught, who also attended the meetings. “Ventripoint isemerging as a rapid, cost-effective alternative to traditional MRIcardiac imaging. It’s now indisputable that our technology enablescaregivers to provide MRI-grade analysis from inferior ultrasounds tomore patients, swiftly and affordably, with high accuracy."
For further information, pleasecontact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
About Ventripoint DiagnosticsLtd.
Ventripoint has become an industry leader in the application of AI(Artificial Intelligence) to echocardiography. Ventripoint's VMSproducts are powered by its proprietary KBR technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe, and Canada.
Forward Looking Statements
This news release contains forward-looking statements andforward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and information address future eventsand conditions, by their very nature they involve inherent risks anduncertainties. Actual results could differ materially from thosecurrently anticipated due to several factors and risks. Factors whichcould materially affect such forward-looking information are describedin the risk factors in the Company's most recent annual management'sdiscussion and analysis that is available on the Company's profile onSEDAR at www.sedar.com. Readers are cautioned that theforegoing list of factors is not exhaustive. The forward-lookingstatements included in this news release are expressly qualified bythis cautionary statement. The forward-looking statements andinformation contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether becauseof new information, future events or otherwise, unless so required byapplicable securities laws.
Copyright (c) 2024 TheNewswire - All rights reserved.